Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 44.38
+4.59 (11.54%)
Jul 10, 2026, 3:00 PM CST
SHA:688319 Market Cap
SHA:688319 has a market cap or net worth of 18.01 billion as of July 10, 2026. Its market cap has increased by 171.95% in one year.
Market Cap
18.01B
Enterprise Value
18.25B
Revenue
774.47M
Ranking
n/a
PE Ratio
318.55
Stock Price
44.38
Market Cap Chart
Since June 8, 2021, SHA:688319's market cap has increased from 16.17B to 18.01B, an increase of 11.35%. That is a compound annual growth rate of 2.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 10, 2026 | 18.01B | 74.90% |
| Dec 31, 2025 | 10.29B | 139.25% |
| Dec 31, 2024 | 4.30B | -32.95% |
| Dec 29, 2023 | 6.42B | 14.17% |
| Dec 30, 2022 | 5.62B | -61.27% |
| Dec 31, 2021 | 14.51B | -10.25% |
| Jun 8, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Xiamen Amoytop Biotech | 22.29B |
| Hebei Changshan Biochemical Pharmaceutical | 20.45B |
| Yili Chuanning Biotechnology | 18.51B |
| Sinocelltech Group | 17.05B |
| Jinyu Bio-technology | 13.74B |
| Anhui Anke Biotechnology (Group) | 13.60B |
| Mabwell (Shanghai) Bioscience | 13.39B |
| BrightGene Bio-Medical Technology | 13.02B |